What is Tenaya Therapeutics Inc?
, a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
, a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 79.59M.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.
| Shares sold | Shares bought | |
|---|---|---|
| 0-3months | 0 | 0 |
| 3-6months | 0 | 0 |
| 6-9months | 24,170,266 shares $2.4M | 0 |
| 9-12months | 54,423,781 shares $3.1M | 0 |